NCT04425213 (COV-OB-ICU) is a clinical trial in COVID, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT04425213?

NCT04425213 is sponsored by Central Hospital, Nancy, France.

What condition does NCT04425213 study?

NCT04425213 studies COVID, Severe Acute Respiratory Syndrome, Obesity, Comorbidities and Coexisting Conditions.

Is NCT04425213 still recruiting?

NCT04425213 is currently completed. Last updated 16 June 2020.

Last reviewed 2020-06-16 · How we verify

NCT04425213: COV-OB-ICU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obesity and Mortality of Critically Ill Patients With COVID-19

Completed Last updated 16 June 2020

What this trial tests

trial in COVID in 250 participants. Completed in 26 May 2020.

Timeline

12 May 2020

Primary endpoint
25 May 2020

26 May 2020

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	250
Start date	12 May 2020
Primary completion	25 May 2020
Estimated completion	26 May 2020
Sites	1 location across France

Conditions studied

COVID — all drugs for COVID →
Severe Acute Respiratory Syndrome — all drugs for Severe Acute Respiratory Syndrome →
Obesity — all drugs for Obesity →
Comorbidities and Coexisting Conditions — all drugs for Comorbidities and Coexisting Conditions →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with COVID or Severe Acute Respiratory Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Disproportionate impact of COVID-19 in patients with obesity is now well established. Obesity is associated with severe forms of COVID-19 and may be a risk factor of intensive care unit (ICU) admission. Obesity is associated with COVID-19 related hospital death in a large United Kingdom cohort study. However, there is a gap of knowledge on assessment of outcomes such as severity of Acute Respiratory Distress syndrome (ARDS), duration of hospitalisation and mortality in ICU. Moreover, an obesity survival paradox has been observed in patients with ARDS. This raises the question whether the obesity paradox has been broken by COVID-19. The investigators aim to explore risk factors of in-ICU death for patient with COVID-19, including obesity and other chronic diseases and to describe the clinical course and outcomes, including the management of acute respiratory failure and other intensive care management.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04425213 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 16 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04425213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing